Relative Children's Lipid Accumulation Product Is a Novel Indicator for Metabolic Syndrome.
adolescents
children
metabolic syndrome
obesity
relative children’s lipid accumulation product
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
12
2020
accepted:
22
02
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
28
12
2021
Statut:
epublish
Résumé
The children's lipid accumulation product (CLAP) is associated with MS in Chinese children and adolescents. The aim of this study was to develop a more effective indicator, the relative children's lipid accumulation product (RCLAP) was evaluated for correlation with MS and the density of lipid accumulation. A stratified cluster sampling method was used to recruit 683 students aged 8-15 years in this study. The presence of MS was defined according to the NCEP-ATP III criteria. The participants' guardians signed informed consent before the medical examination. This study was approved by the Medical Ethics Committee of the Bengbu Medical College [(2015) No.003] and was conducted in accordance with the Declaration of Helsinki. The overall prevalence of MS was 4.8% (male 6.6%, female 2.8%). After adjusting for sedentary activity time, relative children's lipid accumulation product per height (RCLAP-H) and relative children's lipid accumulation product per sitting height (RCLAP-SH) significantly increased the risk of MS in girls [OR (95% CI): 96.13 (11.11-831.97) and 96.13 (11.11-831.97), respectively]. After adjusting for ages and moderate-to-vigorous physical activity time, RCLAP-H, and RCLAP-SH significantly increased the risk of MS in boys [OR (95% CI): 171.75 (33.60-878.00) and 133.18 (27.65-641.39), respectively]. The AUCs of RCLAP-H and RCLAP-SH for predicting MS were 0.950, 0.948 in girls, and 0.952, 0.952 in boys, which were higher than BMI, WHtR, Tg/HDL-C, CLAP, and CLAP combining height, sitting height. The RCLAP-H and RCLAP-SH were more effective indicators for predicting MS than BMI, WHtR, Tg/HDL-C, and CLAP in children and adolescents.
Sections du résumé
Background
The children's lipid accumulation product (CLAP) is associated with MS in Chinese children and adolescents. The aim of this study was to develop a more effective indicator, the relative children's lipid accumulation product (RCLAP) was evaluated for correlation with MS and the density of lipid accumulation.
Methods
A stratified cluster sampling method was used to recruit 683 students aged 8-15 years in this study. The presence of MS was defined according to the NCEP-ATP III criteria. The participants' guardians signed informed consent before the medical examination. This study was approved by the Medical Ethics Committee of the Bengbu Medical College [(2015) No.003] and was conducted in accordance with the Declaration of Helsinki.
Results
The overall prevalence of MS was 4.8% (male 6.6%, female 2.8%). After adjusting for sedentary activity time, relative children's lipid accumulation product per height (RCLAP-H) and relative children's lipid accumulation product per sitting height (RCLAP-SH) significantly increased the risk of MS in girls [OR (95% CI): 96.13 (11.11-831.97) and 96.13 (11.11-831.97), respectively]. After adjusting for ages and moderate-to-vigorous physical activity time, RCLAP-H, and RCLAP-SH significantly increased the risk of MS in boys [OR (95% CI): 171.75 (33.60-878.00) and 133.18 (27.65-641.39), respectively]. The AUCs of RCLAP-H and RCLAP-SH for predicting MS were 0.950, 0.948 in girls, and 0.952, 0.952 in boys, which were higher than BMI, WHtR, Tg/HDL-C, CLAP, and CLAP combining height, sitting height.
Conclusions
The RCLAP-H and RCLAP-SH were more effective indicators for predicting MS than BMI, WHtR, Tg/HDL-C, and CLAP in children and adolescents.
Identifiants
pubmed: 34093432
doi: 10.3389/fendo.2021.645825
pmc: PMC8173219
doi:
Substances chimiques
Lipids
0
Triglycerides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
645825Informations de copyright
Copyright © 2021 Zhang, Zhang, Wang, Yuan, Sun, Gao and Fu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatrics. 2006 Nov;118(5):e1390-8
pubmed: 17079540
Arch Pediatr Adolesc Med. 2009 Apr;163(4):328-35
pubmed: 19349561
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Aug;36(8):884-8
pubmed: 26714549
Am J Med. 2006 Oct;119(10):812-9
pubmed: 17000207
Hypertens Res. 2020 Apr;43(4):305-312
pubmed: 31819153
Med Clin North Am. 1971 Jul;55(4):835-46
pubmed: 5141911
Diabetes Metab Syndr Obes. 2019 Oct 10;12:2075-2083
pubmed: 31632117
J Lipid Res. 2019 Oct;60(10):1710-1719
pubmed: 30097511
PLoS One. 2015 Oct 13;10(10):e0139984
pubmed: 26461112
Prev Med. 2013 Dec;57(6):867-71
pubmed: 24103567
Pediatr Exerc Sci. 2009 Aug;21(3):339-53
pubmed: 19827457
Transl Pediatr. 2017 Oct;6(4):397-407
pubmed: 29184820
BMC Med. 2011 May 05;9:48
pubmed: 21542944
Obesity (Silver Spring). 2006 Mar;14(3):377-82
pubmed: 16648607
Metab Syndr Relat Disord. 2008 Sep;6(3):171-5
pubmed: 18699720
Am J Clin Nutr. 1990 Apr;51(4):571-7
pubmed: 2321565
Metab Syndr Relat Disord. 2018 Apr;16(3):122-126
pubmed: 29412763
Clin Biochem. 2011 Jul;44(10-11):760-6
pubmed: 21620812
Diabetes Care. 2008 Mar;31(3):587-9
pubmed: 18071007
Ann N Y Acad Sci. 2013 Apr;1281:123-40
pubmed: 23356701
Endocrinology. 2003 Dec;144(12):5159-65
pubmed: 12960011
Metab Syndr Relat Disord. 2011 Oct;9(5):389-95
pubmed: 21718129
Front Endocrinol (Lausanne). 2020 Jun 09;11:330
pubmed: 32582026
Diabetes Care. 2004 Sep;27(9):2222-8
pubmed: 15333488
Int J Obes Relat Metab Disord. 2004 Feb;28(2):242-7
pubmed: 14610531
Nature. 2006 Dec 14;444(7121):881-7
pubmed: 17167477
J Pediatr Endocrinol Metab. 2013;26(11-12):1123-30
pubmed: 23751385
BMC Cardiovasc Disord. 2005 Sep 08;5:26
pubmed: 16150143
Nutr Metab Cardiovasc Dis. 2011 Jun;21(6):455-66
pubmed: 21565479
Nutr Hosp. 2013 Nov 01;28(6):1951-60
pubmed: 24506374
Int J Endocrinol. 2014;2014:195407
pubmed: 25574166
J Pediatr. 2004 Oct;145(4):439-44
pubmed: 15480363
Diabetes. 2015 Aug;64(8):2847-58
pubmed: 25845659
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31723976
Compr Physiol. 2012 Apr;2(2):1143-211
pubmed: 23798298
Eat Weight Disord. 2020 Feb;25(1):151-161
pubmed: 29971623
Curr Opin Lipidol. 2003 Jun;14(3):281-7
pubmed: 12840659
Int J Obes Relat Metab Disord. 2004 Jul;28(7):833-41
pubmed: 15170466
Pediatrics. 2001 Feb;107(2):344-50
pubmed: 11158468
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2123-2124
pubmed: 28586453
Diabetes Care. 2004 Oct;27(10):2438-43
pubmed: 15451913
Nutr Metab Cardiovasc Dis. 2016 Jun;26(6):551
pubmed: 27193247
Acta Diabetol. 2015 Oct;52(5):855-63
pubmed: 25690647
Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7
pubmed: 12912790
J Res Med Sci. 2016 Oct 18;21:90
pubmed: 28163736
Int J Obes Relat Metab Disord. 2001 May;25(5):652-61
pubmed: 11360147
J Endocrinol Invest. 2020 Jan;43(1):101-107
pubmed: 31347024
Diabetes Metab Syndr Obes. 2020 May 14;13:1653-1660
pubmed: 32523365
Diabetes Care. 2006 Jan;29(1):151-3
pubmed: 16373916
Diabetes Care. 2004 Oct;27(10):2516-7
pubmed: 15451932
Am J Clin Nutr. 1981 Aug;34(8):1617-21
pubmed: 7270486
Am J Clin Nutr. 2003 Nov;78(5):928-34
pubmed: 14594778